Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | FABP3 | P05413 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6636937 | 0.84 | MYC (0.49) | TDP1L3MBTL1KDM4EALDH1A1HPGD | |
| SCHEMBL4851263 | 0.84 | CA12 (0.52) | TDP1L3MBTL1KDM4EALDH1A1HPGD | |
| SCHEMBL355272 | 0.84 | TDP1 (0.61) | TDP1L3MBTL1KDM4EALDH1A1HPGD | |
| SCHEMBL11466346 | 0.81 | TDP1 (0.59) | TDP1L3MBTL1KDM4EALDH1A1HPGD | |
| SCHEMBL6916441 | 0.81 | TDP1 (0.59) | TDP1L3MBTL1KDM4EALDH1A1HPGD | |
| Bromide SCHEMBL6113408 | 0.81 | TDP1 (0.59) | TDP1L3MBTL1KDM4EALDH1A1HPGD | |
| SCHEMBL6913554 | 0.81 | L3MBTL1 (0.59) | TDP1L3MBTL1KDM4EALDH1A1HPGD | |
| SCHEMBL6907913 | 0.81 | TDP1 (0.59) | TDP1L3MBTL1KDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL6113042 | 0.81 | TDP1 (0.59) | TDP1L3MBTL1KDM4EALDH1A1HPGD | |
| SCHEMBL6916435 | 0.81 | TDP1 (0.59) | TDP1L3MBTL1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042780-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-05 | — | — | US | disclosed |
| CN-120081802-A | Heterocyclic substituted benzamide derivative and application thereof | 南华大学附属第一医院 | 2025-06-03 | — | — | CN | disclosed |
| US-20250170122-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250171453-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-12152032-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-11-21 | — | — | US | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20050096358-A1 | Substituted biaryl amides as C5A receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2005-05-05 | — | — | US | disclosed |
| US-6858637-B2 | Treating rheumatoid arthritis, psoriasis, cardiovascular disease, reperfusion injury, and bronchial asthma; e.g., 2-Methoxynaphthalene-1-carboxylic acid benzyl-indan-2-yl-amide | NEUROGEN CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1487796-A1 | SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040235792-A1 | Serine protease inhibitors compromising a hydrogen-bond acceptor | TRIGEN LIMITED (GB) | 2004-11-25 | — | — | US | disclosed |
| US-20040048913-A1 | Substituted biaryl amides as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2004-03-11 | — | — | US | disclosed |
| WO-2003082826-A1 | SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| US-20030181759-A1 | Process for the preparation of 2-halobenzoic acids | NIHON NOHYAKU CO., LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1277726-A1 | PROCESS FOR THE PREPARATION OF 2-HALOBENZOIC ACIDS | Nihon Nohyaku Co., Ltd. (JP) | 2003-01-22 | — | — | EP | disclosed |
| WO-2002057273-A9 | SERINE PROTEASE INHIBITORS COMPRISING A HYDROGEN-BOND ACCEPTOR | TRIGEN LTD (GB) | 2002-11-28 | — | — | WO | disclosed |
| US-4284619-A | INJECTING RADIOIODINE COMPOUND | MEDI-PHYSICS, INC. (US) | 1981-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | TDP1 872/4885L3MBTL1 917/4885KDM4E 1254/4885 |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CD | TDP1 1022/4885L3MBTL1 3938/4885KDM4E 4071/4885 |
| US-20040048913-A1 | Substituted biaryl amides as C5a receptor modulators | C5AR1, C5AR2, C3AR1 | TDP1 4028/4885L3MBTL1 1782/4885KDM4E 3896/4885 |
| US-20050096358-A1 | Substituted biaryl amides as C5A receptor modulators | C5AR1, C5AR2, C3AR1 | TDP1 4185/4885L3MBTL1 1859/4885KDM4E 3737/4885 |
| US-20260042780-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PTEN, PIK3C2A, PIK3CA | TDP1 2752/4885L3MBTL1 3878/4885KDM4E 3458/4885 |
| US-20250170122-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | TDP1 1142/4885L3MBTL1 4132/4885KDM4E 4349/4885 |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | TDP1 3692/4885L3MBTL1 4510/4885KDM4E 454/4885 |
| US-12152032-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | TDP1 890/4885L3MBTL1 4198/4885KDM4E 3893/4885 |
| US-20040235792-A1 | Serine protease inhibitors compromising a hydrogen-bond acceptor | SERPINB1, SPINT2, CTRL | TDP1 1912/4885L3MBTL1 683/4885KDM4E 2330/4885 |
| US-20250171453-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | TDP1 890/4885L3MBTL1 4198/4885KDM4E 3893/4885 |
| US-20030181759-A1 | Process for the preparation of 2-halobenzoic acids | HAO2, CBR1, AOC2 | TDP1 4038/4885L3MBTL1 1007/4885KDM4E 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.